Compare EVTV & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTV | DARE |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6M | 21.6M |
| IPO Year | 2014 | 2014 |
| Metric | EVTV | DARE |
|---|---|---|
| Price | $1.72 | $1.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 904.0K | 97.9K |
| Earning Date | 04-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,939,008.00 | $2,807,885.00 |
| Revenue This Year | N/A | $3,195.79 |
| Revenue Next Year | N/A | $95.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 217.58 | N/A |
| 52 Week Low | $0.15 | $1.27 |
| 52 Week High | $5.07 | $9.19 |
| Indicator | EVTV | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 49.68 | 54.90 |
| Support Level | $1.63 | $1.67 |
| Resistance Level | $2.40 | $1.84 |
| Average True Range (ATR) | 0.14 | 0.13 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 45.54 | 69.81 |
Envirotech Vehicles Inc is a provider of purpose-built zero-emission electric vehicles focused on reducing the total cost of vehicle ownership and helping fleet operators unlock the benefits of green technology. It recognizes revenue from the sales of zero-emission electric vehicles and vehicle maintenance and inspection services. The Company serves commercial and last-mile fleets, school districts, public and private transportation service companies and colleges and universities to meet the increasing demand for light to heavy-duty electric vehicles.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.